WO2001007646A3 - Verfahren zur quantifizierung der antiviralen wirkung antiviraler wirkstoffe - Google Patents

Verfahren zur quantifizierung der antiviralen wirkung antiviraler wirkstoffe Download PDF

Info

Publication number
WO2001007646A3
WO2001007646A3 PCT/DE2000/002428 DE0002428W WO0107646A3 WO 2001007646 A3 WO2001007646 A3 WO 2001007646A3 DE 0002428 W DE0002428 W DE 0002428W WO 0107646 A3 WO0107646 A3 WO 0107646A3
Authority
WO
WIPO (PCT)
Prior art keywords
antiviral
viral
active principles
during
marking substance
Prior art date
Application number
PCT/DE2000/002428
Other languages
English (en)
French (fr)
Other versions
WO2001007646A2 (de
Inventor
Martin Heinkelein
Gergely Jarmy
Christian Jassoy
Axel Rethwilm
Benedikt Weissbrich
Original Assignee
Martin Heinkelein
Gergely Jarmy
Christian Jassoy
Axel Rethwilm
Benedikt Weissbrich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19951327A external-priority patent/DE19951327A1/de
Application filed by Martin Heinkelein, Gergely Jarmy, Christian Jassoy, Axel Rethwilm, Benedikt Weissbrich filed Critical Martin Heinkelein
Priority to AU72680/00A priority Critical patent/AU7268000A/en
Publication of WO2001007646A2 publication Critical patent/WO2001007646A2/de
Publication of WO2001007646A3 publication Critical patent/WO2001007646A3/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Die Erfindung betrifft ein Verfahren zur Quantifizierung der antiviralen Wirkung antiviraler Wirkstoffe mit den folgenden Verfahrenstufen: a) mit einem replikationsinkompetenten oder attenuierten viralen Vektor, enthaltend alle erforderlichen genetischen Informationen zur Infektion einer Zelle mit einem Zielvirustypus, wobei der virale Vektor zusätzlich genetische Information zur Expression einer Markersubstanz in der infizierten Zelle enthält und wobei zusätzlich zu einem viralen Gen zumindest eine weitere virale Sequenz derart verändert ist, daß in einer transduzierten Zelle keine Virusbestandteile oder keine potentiell pathogenen Viren gebildet werden können, werden Zellen transduziert, b) vor, während und/oder nach der Transduktion und/oder ggf. vor, während und/oder nach Induktion der Vektor-DNA-Transkription wird ein prospektiver antiviraler Wirkstoff in einer definierten Dosis zu den Zellen gegeben, c) die Aktivität an exprimierter Markersubstanz wird quantitativ analysiert und eine Reduktion, bezogen auf eine Aktivität an exprimierter Markersubstanz bei einer Transduktion und/oder Induktion ohne Zugabe antiviraler Wirkstoffe, bestimmt.
PCT/DE2000/002428 1999-07-21 2000-07-19 Verfahren zur quantifizierung der antiviralen wirkung antiviraler wirkstoffe WO2001007646A2 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU72680/00A AU7268000A (en) 1999-07-21 2000-07-19 Method for quantization of the antiviral effect of antiviral active principles

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE19934917 1999-07-21
DE19934917.7 1999-07-21
DE19951327.9 1999-10-20
DE19951327A DE19951327A1 (de) 1999-07-21 1999-10-20 Verfahren zur Quantifizierung der antiviralen Wirkung antiviraler Wirkstoffe

Publications (2)

Publication Number Publication Date
WO2001007646A2 WO2001007646A2 (de) 2001-02-01
WO2001007646A3 true WO2001007646A3 (de) 2001-05-17

Family

ID=26054336

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2000/002428 WO2001007646A2 (de) 1999-07-21 2000-07-19 Verfahren zur quantifizierung der antiviralen wirkung antiviraler wirkstoffe

Country Status (2)

Country Link
AU (1) AU7268000A (de)
WO (1) WO2001007646A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9067966B2 (en) 2009-07-14 2015-06-30 Hetero Research Foundation, Hetero Drugs Ltd. Lupeol-type triterpene derivatives as antivirals
WO2011061590A1 (en) 2009-11-17 2011-05-26 Hetero Research Foundation Novel carboxamide derivatives as hiv inhibitors
WO2011080562A1 (en) 2009-12-29 2011-07-07 Hetero Research Foundation Novel aza-peptides containing 2,2-disubstituted cyclobutyl and/or substituted alkoxy benzyl derivatives as antivirals
WO2012095705A1 (en) 2011-01-10 2012-07-19 Hetero Research Foundation Pharmaceutically acceptable salts of novel betulinic acid derivatives
WO2014105926A1 (en) 2012-12-31 2014-07-03 Hetero Research Foundation Novel betulinic acid proline derivatives as hiv inhibitors
US20170129916A1 (en) 2014-06-26 2017-05-11 Hetero Research Foundation Novel betulinic proline imidazole derivatives as hiv inhibitors
MA40886B1 (fr) 2015-02-09 2020-03-31 Hetero Research Foundation Nouveau triterpénone en c-3 avec des dérivés d'amide inverse en c-28 en tant qu'inhibiteurs du vih
WO2016147099A2 (en) 2015-03-16 2016-09-22 Hetero Research Foundation C-3 novel triterpenone with c-28 amide derivatives as hiv inhibitors
ES2965305T3 (es) 2019-02-11 2024-04-12 Hetero Labs Ltd Nuevos derivados de triterpeno como inhibidores del VIH

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0361749A1 (de) * 1988-09-27 1990-04-04 Dana Farber Cancer Institute Vektor, der ein replikationskompetentes HIV-I-Provirus und ein heterologes Gen enthält
WO1991019798A1 (en) * 1990-06-20 1991-12-26 Dana Farber Cancer Institute Vectors containing hiv packaging sequences, packaging defective hiv vectors, and uses thereof
WO1998012338A1 (en) * 1996-09-21 1998-03-26 Viromedica Pacific Limited Improved retroviral vectors for gene therapy
US5837464A (en) * 1996-01-29 1998-11-17 Virologic, Inc. Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
WO1999006597A1 (en) * 1997-07-30 1999-02-11 Virologic, Inc. Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0361749A1 (de) * 1988-09-27 1990-04-04 Dana Farber Cancer Institute Vektor, der ein replikationskompetentes HIV-I-Provirus und ein heterologes Gen enthält
WO1991019798A1 (en) * 1990-06-20 1991-12-26 Dana Farber Cancer Institute Vectors containing hiv packaging sequences, packaging defective hiv vectors, and uses thereof
US5837464A (en) * 1996-01-29 1998-11-17 Virologic, Inc. Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
WO1998012338A1 (en) * 1996-09-21 1998-03-26 Viromedica Pacific Limited Improved retroviral vectors for gene therapy
WO1999006597A1 (en) * 1997-07-30 1999-02-11 Virologic, Inc. Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DULL T ET AL: "A THIRD-GENERATION LENTIVIRUS VECTOR WITH A CONDITIONAL PACKAGING SYSTEM", JOURNAL OF VIROLOGY,US,THE AMERICAN SOCIETY FOR MICROBIOLOGY, vol. 72, no. 11, November 1998 (1998-11-01), pages 8463 - 8471, XP000872456, ISSN: 0022-538X *
KIM V N ET AL: "MINIMAL REQUIREMENT FOR A LENTIVIRUS VECTOR BASED ON HUMAN IMMUNODEFICIENCY VIRUS TYPE 1", JOURNAL OF VIROLOGY,US,THE AMERICAN SOCIETY FOR MICROBIOLOGY, vol. 72, no. 1, January 1998 (1998-01-01), pages 811 - 816, XP000872453, ISSN: 0022-538X *

Also Published As

Publication number Publication date
AU7268000A (en) 2001-02-13
WO2001007646A2 (de) 2001-02-01

Similar Documents

Publication Publication Date Title
Evans et al. Relocalization of the Mre11-Rad50-Nbs1 complex by the adenovirus E4 ORF3 protein is required for viral replication
Goodrum et al. Roles for the E4 orf6, orf3, and E1B 55-kilodalton proteins in cell cycle-independent adenovirus replication
Drayman et al. HSV-1 single-cell analysis reveals the activation of anti-viral and developmental programs in distinct sub-populations
Lo Cigno et al. Human papillomavirus E7 oncoprotein subverts host innate immunity via SUV39H1-mediated epigenetic silencing of immune sensor genes
Esteban et al. Early virus protein synthesis in vaccinia virus-infected cells
Forrester et al. Serotype-specific inactivation of the cellular DNA damage response during adenovirus infection
Everett et al. Analysis of the functions of herpes simplex virus type 1 regulatory protein ICP0 that are critical for lytic infection and derepression of quiescent viral genomes
Yu et al. Herpes simplex virus type 1 cleavage and packaging proteins UL15 and UL28 are associated with B but not C capsids during packaging
Mendelson et al. Detection of endogenous human cytomegalovirus in CD34+ bone marrow progenitors
Karen et al. Adenovirus core protein VII protects the viral genome from a DNA damage response at early times after infection
Martinez-Guzman et al. Transcription program of murine gammaherpesvirus 68
Komatsu et al. In vivo labelling of adenovirus DNA identifies chromatin anchoring and biphasic genome replication
Pedersen et al. Characterization of vaccinia virus intracellular cores: implications for viral uncoating and core structure
Sohn et al. Adenoviral strategies to overcome innate cellular responses to infection
AUPN477695A0 (en) Gene therapy
Esclatine et al. The UL41 protein of herpes simplex virus mediates selective stabilization or degradation of cellular mRNAs
Pesola et al. Herpes simplex virus 1 immediate-early and early gene expression during reactivation from latency under conditions that prevent infectious virus production
Sen et al. Distinctive roles for type I and type II interferons and interferon regulatory factors in the host cell defense against varicella-zoster virus
WO2001007646A3 (de) Verfahren zur quantifizierung der antiviralen wirkung antiviraler wirkstoffe
Marcellus et al. Expression of p53 in Saos-2 osteosarcoma cells induces apoptosis which can be inhibited by Bcl-2 or the adenovirus E1B-55 kDa protein.
Genoveso et al. Formation of adenovirus DNA replication compartments and viral DNA accumulation sites by host chromatin regulatory proteins including NPM1
Veeranna et al. Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen induction by hypoxia and hypoxia-inducible factors
Yan et al. Developing novel oncolytic adenoviruses through bioselection
Zanzinger et al. High frequency of finding double-stranded RNA in naturally occurring isolates of Rhizoctonia solani
Ushijima et al. Herpes simplex virus UL56 interacts with and regulates the Nedd4-family ubiquitin ligase Itch

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU BA BB BG BR BY CA CH CN CR CU CZ DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU BA BB BG BR BY CA CH CN CR CU CZ DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP